Hemab Therapeutics priced an upsized initial public offering, selling 16.75 million shares at $18 per share to raise $301.5 million in gross proceeds, with an additional $45 million possible if underwriters fully exercise their option. The company is set to begin trading on Nasdaq under the ticker COAG. Hemab’s lead programs target coagulation disorders, including Glanzmann thrombasthenia and von Willebrand disease. The IPO reflects continued appetite for specialty biotechs despite the broader market’s early-year volatility. For investors and the sector, the deal adds capital to rare-disease-focused development at a time when public listings have resumed with larger-than-expected size. Management’s ability to deploy funds toward pivotal and late-stage readiness will be the central follow-up as the company enters public ownership.